RyosukeTsugitomi· @Rtsugitom · X·· 2 days agoScore70
Body · original
Day 3 of #ESMO26 is about to begin!
Another exciting day ahead, packed with highly anticipated presentations, including KRASCENDO and SAFFRON!
0 likes · 0 reposts · 0 replies
Conference abstracts
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgSource: RyosukeTsugitomi · x.com
